Baseline Patient Characteristics and Results for Each Study Included in Meta-Analysis
| Study | Kennedy | Paprottka | Lacin | King | Cao | Kalinowski | Rhee | Saxena | Ezzidin | Arslan | Murthy | Ozao-Choy |
| Study year | 2008 | 2011 | 2011 | 2007 | 2010 | 2008 | 2008 | 2010 | 2012 | 2011 | 2008 | 2013 |
| No. of procedures with response assessment | 168 | 40 | 10 | 33 | 51 | 9 | 16 | 48 | 23 | 10 | 8 | 19 |
| Pancreatic NETs* | 19% | 23% | 30% | 24% | 27% | 11% | 20% | 31% | 61% | 20% | 75% | 17% |
| Carcinoid NETs* | 82% | 83% | N/A | 74% | 82% | N/A | 81% | 71% | N/A | 80% | 25% | 78% |
| Mean activity (GBq) | 1.31 | 1.63 | 1.35 | 1.99 | 1.8 | 2.1† | N/A | 1.94 | 3.4 | 1.49 | 1.23† | N/A |
| Extrahepatic disease | N/A | N/A | 38% | 59% | 49% | 22% | N/A | 48% | 61% | 50% | 63% | N/A |
| Liver replacement by tumor | ||||||||||||
| ≤24% or ≤25% | N/A | 20% | N/A | 32% | 35% | N/A | N/A | 35% | 13% | 20% | N/A | N/A |
| 25%–50% or 26%–50% | N/A | 70% | N/A | 41% | 53% | N/A | N/A | 38% | 39% | 80% | N/A | N/A |
| >50% or ≥50% | N/A | 10% | N/A | 27% | 12% | N/A | N/A | 27% | 48% | 0% | N/A | 65% |
| Mean | N/A | N/A | N/A | 32% | N/A | 57% | N/A | 32% | N/A | N/A | 55% | N/A |
| Prior therapies | ||||||||||||
| Surgery | N/A | 95% | 38.5% | 30.3% | 33.3% | 88.9% | 40% | 39.5% | 17.3% | N/A | 25% | N/A |
| Chemotherapy | N/A | 45% | N/A | 15.2% | 37.3% | 44.4% | N/A | 52% | 34.7% | 100% | 87.5% | N/A |
| Other IAT | N/A | 45% | 23.1% | N/A | 9.8% | 55.6% | 0% | 14.5% | N/A | N/A | 100% | N/A |
| Time of response assessment (mo) | 3 | 3 | 1.5 | 4–60‡ | 1–61‡ | 3 | 6§ | 1–63‡ | 3 | 4–28‡ | 2–15‡ | 1–2.5‡ |
| Complete response‖ | 3% | 0% | 10% | 18.2% | 11.7% | 0% | 0% | 14.5% | 0% | 30% | 0% | 10.5% |
| Partial response‖ | 66.7% | 22.5% | 40% | 33.3% | 27.5% | 66.7% | 50% | 39.5% | 30.4% | 50% | 12.5% | 47% |
| Stable disease‖ | 25% | 75% | 40% | 15.2% | 27.5% | 33.3% | 43.7% | 23% | 60.9% | 10% | 50% | 32% |
| Progressive disease‖ | 5.3% | 2.5% | 10% | 33.3% | 33.3% | 0% | 6.3% | 23% | 8.7% | 10% | 37.5% | 10.5% |
| Median survival (mo) | 70 | N/A | 18 | N/A | 36 | N/A | 28 | 35 | 29 | N/A | 14 | N/A |
| One-year survival | N/A | N/A | 85% | N/A | 86% | 100% | N/A | 87% | N/A | N/A | N/A | N/A |
↵* Percentages of pancreatic and carcinoid NETs do not necessarily add up to 100% because sometimes there is overlap in and/or inconsistent/incomplete recording of location and/or histology.
↵† These studies reported median activity level.
↵‡ These studies provided a follow-up range, but didn’t explicitly state when RECIST was recorded. In most studies best response was given.
↵§ This study reported RECIST within 6 mo after treatment.
↵‖ All response rates are per RECIST, except the Kennedy study, which used RECIST or World Health Organization criteria.
N/A: not available; IAT: intraarterial therapies